Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Milestone Pharmaceuticals Analyst Ratings
TD Cowen Downgrades Milestone Pharmaceuticals(MIST.US) to Hold Rating
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating
Milestone Pharmaceuticals Analyst Ratings
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals Analyst Ratings
Strategic Catalysts and Market Potential Drive Buy Rating for Milestone Pharmaceuticals' CARDAMYST
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Milestone Pharmaceuticals (MIST) Gets a Buy From Piper Sandler